Table 2.
Laboratory Adverse Events
| Laboratory Adverse Eventsa | Number of patients, N = 54, n (%) | |
|---|---|---|
| Grade 1–2b | Grade 3–4c | |
| Hematologic | ||
| Thrombocytopenia | 34 (63) | 4 (7) |
| Anemia | 32 (59) | 4 (7) |
| Leukopenia | 28 (52) | 1 (2) |
| Neutropenia | 15 (28) | 1 (2) |
| Lymphopenia | 7 (13) | 4 (7) |
| Hepatic | ||
| AST elevation | 16 (30) | 0 |
| ALT elevation | 13 (24) | 1 (2) |
| Alkaline phosphatase elevation | 13 (24) | 1 (2) |
| Hypoalbuminemia | 9 (17) | 0 |
| Hyperbilirubinemia | 4 (4) | 1 (2) |
| Lipids | ||
| Hypercholesterolemia | 29 (53) | 0 |
| Hypertriglyceridemia | 22 (41) | 1 (2) |
| Metabolic | ||
| Proteinuria | 27 (50) | 1 (2) |
| Hyperglycemia | 19 (35) | 2 (4) |
| Elevated Creatinine | 14 (26) | 0 |
| Hypokalemia | 11 (20) | 5 (9) |
| Hypocalcemia | 6 (11) | 0 |
| Hypophosphatemia | 3 (6) | 3 (6) |
| Coagulation | ||
| Prolonged aPTT | 3 (6) | 0 |
a
National Cancer Institute Common Terminology Criteria for Adverse Events, criteria 3.0.
b
Grade 1–2 adverse events that were possibly, probably, or definitely related to study treatment, and occurred greater than or equal to 5% of the time.
c
Grade 3–4 adverse events that were possibly, probably, or definitely related to study treatment, regardless of frequency.